A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Third-generation Aromatase Inhibitors and Tamoxifen
1. Patients with early breast cancer who are scheduled to receive endocrine therapy with
tamoxifen or any of the third-generation aromatase inhibitors, anastrozole, letrozole
2. No major rheumatological disorders such as severe rheumatoid arthritis.
3. Patients must have provided informed consent for participation in this study.
1. Concomitant endocrine therapy for breast cancer.
2. Concomitant intake of sex hormone containing drugs such as hormone replacement
Type of Study:
Time Perspective: Prospective
To assess the effect of BMI on loss of grip strength measured by a modified sphygmomanometer with baseline, month 3, month 6 and month 12 measurements.
measurements occur at baseline, 3 months, 6 months and 12 months
Outcome Time Frame:
Patrick Neven, MD PhD
University Hospitals Leuven
Belgium: Federal Agency for Medicinal Products and Health Products
- Breast Cancer
- breast cancer
- aromatase inhibitors
- grip strength
- Breast Neoplasms